ArticleKidney international reports2022

Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.

Andrew S Bomback et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.